Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

April 2024

Long-term efficacy and safety following switch between upadacitinib and adalimumab in patients with rheumatoid arthritis: 5-Year data from SELECT-COMPARE

Rheumatol Ther 2024 doi: 10.1007/s40744-024-00658-1 Epub ahead of print

Song Y,

Penn SK,

McDearmon-Blondell E,

Khan N,

Chan K,

Mysler E

Fleischmann, et al. found that patients who switched from adalimumab to upadacitinib and vice versa following lack of improvement showed improvements in disease activity measures and functional outcomes through 228 weeks.

Keywords:

Risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors in cardiovascular risk-enriched rheumatoid arthritis patients

Arthritis Rheumatol 2024 doi: 10.1002/art.42846 Epub ahead of print https://pubmed.ncbi.nlm.nih.gov/38481002/

Koch GG,

Wang C,

Chen AS,

Menon S,

Chen Y,

Lee K,

Szekanecz Z

This post hoc analysis of ORAL Surveillance showed that incidence of venous thromboembolism (VTE) events was higher in patients with RA treated with tofacitinib (10>5mg BID) versus TNFi. Across treatments, VTE risk factors (age, BMI, and VTE history) were aligned with previous studies in the general RA population.

Keywords:

December 2023

MACE e VTE nos programas de ensaios clínicos de upadacitinibe em artrite reumatoide, artrite psoriática e espondilite anquilosante

RMD Open 2023; 9(4):e003392 doi 10.1136/rmdopen-2023-003392

Choy E,

Nash P,

Lippe R,

Khan N,

Shmagel AK,

Palac H,

Suboticki J,

Curtis JR

Rates of MACE and VTE events in patients with RA or PsA treated are consistent across 15 mg and 30 mg doses of upadacitinib, and comparable with active comparators adalimumab and MTX. Several risk factors were also identified for MACE and VTE events in patients with RA.

Keywords:

July 2023

Perfil de segurança de upadacitinibe em pacientes com risco cardiovascular: análise post hoc integrada do programa clínico de fase III SELECT na artrite reumatoide

Ann Rheum Dis. 2023 doi: 10.1136/ard-2023-223916

Palac H,

Liu J,

Pots hoc analysis of safety data in patients with RA at increased risk of CV events from the upadacitinib SELECT phase III RA clinical programme helps to contextualise the overall risk profile of upadacitinib.

Keywords:

March 2023

Perfil de Segurança de Upadacitinibe em Mais de 15.000 Pacientes-Ano em Artrite Reumatoide, Artrite Psoriática, Espondilite Anquilosante e Dermatite Atópica

RMD Open. 2023;9(1):e002735 doi: 10.1136/rmdopen-2022-002735

Nash P,

Liu J,

Palac H,

Shaw T,

Mease PJ,

Guttman-Yassky E

Integrated analysis of the safety profile of upadacitinib demonstrates that it was generally well-tolerated in RA, PsA, AS and AD, with no new safety risks identified, compared with previous reports.

Keywords:

December 2022

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Ann Rheum Dis. 2022. Epub ahead of print [05/12/2022] doi: 10.1136/ard-2022-223356

Pope JE,

Balsa A,

Buch MH,

Li Z,

Nash P,

Poor G,

van der Helm-van Mil A,

Smolen, et al. provide a 2022 update of the EULAR recommendations for the management of RA with synthetic and biological DMARDs.

Keywords:

EULAR

September 2022

Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update

doi: 10.1136/ard-2022-222784.

Choy EH,

Combe B,

Crow MK,

Emery P,

Gabay C,

Nash P,

Poor G,

Blocking the IL-6R is a major therapeutic advance for many diseases in adults and children. Updated consensus statement provides guidance to rheumatologists and other experts, as well as patients and administrators, on managing patients with the use of drugs blocking the IL-6 pathway.

Keywords:

IL-6,
Review

March 2022

Eficácia e Segurança a longo prazo com upadacitinib ou adalimumabe em pacientes com artrite reumatoide: resultados ao longo de 3 anos do estudo SELECT-COMPARE

RMD Open. 2022;8(1):e002012 doi: 10.1136/rmdopen-2021-002012

Durez P,

Khan N,

Bu X,

Li Y,

Song IH

Upadacitinib continues to show consistently better clinical responses, compared with adalimumab, through 3 years, including rates of remission and low disease activity, physical function and pain severity.Following the favourable upadacitinib efficacy data seen in the SELECT-COMPARE study at 72 weeks, Fleischmann, et al. assessed the long-term safety and efficacy of upadacitinib versus adalimumab over 3 years in the long-term extension of this study, with promising results. ...

Keywords:

January 2022

Inibição da progressão do dano estrutural articular com upadacitinib em artrite reumatoide: resultados de um ano do programa de fase 3 SELECT

Rheumatology (Oxford). 2021. Epub ahead of print. doi: 10.1093/rheumatology/keab861

Hall S,

Durez P,

Shaw T,

Li Y,

Chen S,

Song IH

Keywords:

Taxas de incidência de doença intersticial pulmonar em pacientes com artrite reumatoide tratados com tofacitinib

J Clin Rheumatol. 2021;27(8):e482–e490

Park JK,

Kwok K,

Wang L,

Ponce de Leon D

This post hoc analysis of pooled data from 21 clinical trials in the tofacitinib clinical trial programme highlights the importance of identifying known risk factors of RA-interstitial lung disease (ILD) in clinical practice.Citera, et al. investigated incidence rates of ILD – an extra-articular manifestation of RA – in patients with RA, receiving tofacitinib 5 or 10 mg BID and sort to identify potential risk factors for ILD in these patients....